Ignite Creation Date:
2025-12-25 @ 1:44 AM
Ignite Modification Date:
2026-02-27 @ 10:39 AM
Study NCT ID:
NCT04100694
Status:
APPROVED_FOR_MARKETING
Last Update Posted:
2025-05-20
First Post:
2019-09-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Sponsor:
Merus N.V.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
MCLA-128-CL99; MCLA-128-CL98
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None